Less than a tenth of people eligible to benefit from weight-loss injections including Wegovy can access them, states the World Health Organization as it publishes its first advice on the medications.
Given over a billion people worldwide now classified as obese, it is calling for increased and just availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our latest guidelines recognises that obesity is a chronic disease that can be managed with thorough and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major barriers to widespread availability to the injections that can help people shift considerable body mass, notes the agency.
Skinny Jab Scarcity
Even under the current most favorable case, the supply of these medications could only cover approximately 100 million people – under 10% of the global need, according to the health organization.
The recommendation calls on governments and firms to widen availability, through measures like voluntary licensing.
The intellectual property rights on semaglutide – the core component of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Weight-Loss Jabs Operate
GLP-1 drugs mimick a natural hormone to delay gastric emptying, reduce hunger and boost satiety so individuals consume fewer calories.
People commonly begin shedding pounds after several weeks of beginning the once-weekly jabs.
Research indicates users may see weight return within a year of stopping the treatment, because their usual appetite resume.
To be overweight or obese elevates your risk for contracting diseases, such as type 2 diabetes, heart disease, brain attack, and certain malignancies.
Obesity impacts individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
